Picture of Biomarin Pharmaceutical logo

BMRN Biomarin Pharmaceutical Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapFalling Star

Annual cashflow statement for Biomarin Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-23.8859-64.1142168
Depreciation
Deferred Taxes
Non-Cash Items15123421080.8269
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-101-22466-96.4-337
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Payable / Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities48.385.4305176159
Capital Expenditures-163-138-119-132-108
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items13283.9-247112-3.63
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities-31-53.6-366-20-111
Financing Cash Flow Items-101-44.6-46.2-85.4-85.8
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-74.7181-0.048-18.6-18.7
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-56.5212-61.913730.6